Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies

Hirata, Koichi; Takeshima, Takao; Sakai, Fumihiko; Imai, Noboru; Matsumori, Yasuhiko; Tatsuoka, Yoshihisa; Numachi, Yotaro; Yoshida, Ryuji; Peng, Cheng; Mikol, Daniel D.; Lima, Gabriel Paiva da Silva; Cheng, Sunfa

doi:10.1002/brb3.2526

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the first month of the DBTP, a significant difference in the MMD could be observed between erenumab (− 4.09 days) and topiramate (− 2.77 days: mean difference: − 1.32; 95% CI: − 1.96; − 0.68 days; p < 0.001). This analysis confirms the early onset of efficacy of erenumab as reported in several previous studies [ 30 , 31 ] and the difference was maintained over the entire DBTP (Fig. 3 ).…”

Section: Resultssupporting

confidence: 91%

Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study

et al. 2022

View full text Add to dashboard Cite

Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy of erenumab with topiramate in patients who completed the trial on study medication. Methods Post hoc sensitivity analysis was performed using the full analysis set. Outcomes assessed included the proportion of patients with a ≥50% reduction in monthly migraine days (MMD) from baseline (50% responder rate), over the last 3 months (months 4, 5, and 6) of the double-blind treatment phase (DBTP), the 50% responder rate during the first month of the DBTP, and change from baseline in MMD during the DBTP. Multiple imputation was done for efficacy values of patients who discontinued study treatment. Results Patients (N = 777) were randomly assigned (1:1) to either 70 or 140 mg/month erenumab (N = 389) or 50–100 mg/day topiramate (N = 388). Of these, 334 patients (85.9%) receiving erenumab, and 231 patients (59.5%) receiving topiramate completed the DBTP on study medication. Patients on study medication until the end of the DBTP received a mean dose of 119 mg/month for erenumab and 92 mg/day for topiramate. At month 1, a significantly greater proportion of patients receiving erenumab (39.2%) reported ≥50% reduction in MMD from baseline compared with those receiving topiramate (24.0%; p < 0.001). In the last 3 months, a significantly larger proportion of patients receiving erenumab (60.3%) achieved ≥50% reduction in MMD from baseline compared with those receiving topiramate (43.3%; p < 0.001). Patients receiving erenumab demonstrated significantly greater reductions in MMD during the last 3 months from baseline versus those receiving topiramate (− 6.13 vs − 4.90; 95% CI: − 1.87 to − 0.61; p < 0.001). Conclusions This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD with an early onset of efficacy. Trial registration ClinicalTrials.gov NCT03828539.

show abstract